Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv
Mandate

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

January 14, 2026

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.

The purchase price amounted to USD 91 million. Furthermore, Orexo is entitled to a contingent consideration of up to USD 16.8 million, based on future Zubsolv net sales during 2026 and 2027. Steptoe LLP acted as lead legal counsel in connection with the transaction and Vinge advised Orexo in relation to Swedish law.

Vinge’s team consisted of Rikard Lindahl, Viveka Classon, Kim Bergman Aldevinge and Sara Stålebring.

Related

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

 Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026

Vinge advises PPI Public Property Invest AB (publ) in connection with cross-border merger and listing on Nasdaq Stockholm and Euronext Oslo Børs

 Vinge has advised PPI Public Property Invest AB (publ) (“PPI”) in connection with its listing on Nasdaq Stockholm and secondary listing on Euronext Oslo Børs. The listing was carried out through a cross-border merger whereby PPI absorbed Public Property Invest ASA, whose shares were previously listed on Euronext Oslo Børs.
May 20, 2026

Vinge represents Triton in connection with the sale of Aleris

 Vinge has represented Triton in connection with the sale of Aleris to Mehiläinen Group.
May 18, 2026